Key Takeaways
Contemporary Amperex Technology Co. Ltd. (CATL) shares (3750.HK) jumped 2.61% to HK$648 after Morgan Stanley upgraded the battery giant to Overweight and raised its price target, citing rapid technology adoption.
"We expect CATL's next-gen sodium-ion batteries and condensed batteries to rapidly scale up, likely driving faster revenue growth and a persistent increase in market share over the next three years," Morgan Stanley said in a note. The bank now forecasts a compound annual growth rate for net profit of 30% for 2026-28, up from a previous 25%.
The investment bank's move reflects a significant increase in conviction on the world's largest battery maker. The new price target of HK$815 is a 17% increase from the prior target of approximately HK$697.
The upgrade follows a major capital influx for the battery manufacturer. CATL recently raised approximately $5 billion through a new H-share placement to fund its global expansion and research efforts. This financial maneuver appears to be part of a larger strategy to commercialize cheaper alternatives to lithium-ion batteries. The company recently secured a landmark 60 gigawatt-hour contract for its sodium-ion batteries with energy storage specialist HyperStrong, the largest deal of its kind in the industry.
Morgan Stanley's thesis centers on the rapid deployment of these next-generation cells. CATL's "Naxtra" sodium-ion series boasts an energy density of 175 watt-hours per kilogram and can operate effectively in extreme cold. This technology, along with its high-performance "Shenxing" lithium-iron-phosphate cells, could allow CATL to sidestep lithium supply constraints and solidify its dominance against Western competitors.
The upgrade suggests Morgan Stanley believes CATL's recent capital investments will translate directly into accelerated growth. For investors, the key indicator will be the pace of mass production and adoption of these new battery platforms across global markets. The next catalyst will be the company's upcoming earnings reports, which will be scrutinized for evidence of this technological scale-up impacting revenue and margins.
This article is for informational purposes only and does not constitute investment advice.
